https://doi.org/10.1038/s41375-021-01485-x
V
Versha Banerji
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
160
Papers
3.0K
Citations
26
h-index
50
i10-index
Versha Banerji is an academic researcher from CancerCare Manitoba. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 26, co-authored 136 publications.
ORCID: 0000-0002-7415-8818Papers by this author
worksEfficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
2022 · Leukemia · 194 citations
AI is a viable alternative to high throughput screening: a 318-target study
2024 · Scientific Reports · 114 citations
https://doi.org/10.1038/s41598-024-54655-z
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
2019 · Blood · 61 citations
https://doi.org/10.1182/blood-2019-128404
SYK regulates mTOR signaling in AML
2013 · Leukemia · 51 citations
https://doi.org/10.1038/leu.2013.89
Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling
2014 · Cell Death and Disease · 14 citations
https://doi.org/10.1038/cddis.2014.391
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025 · Cancer Cell · 2 citations
https://doi.org/10.1016/j.ccell.2025.03.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat